The Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), as a single agent, for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC).
The approval was based on data from the KEYNOTE-091 trial (ClinicalTrials.gov Identifier: NCT02504372), a randomized, triple-blind, placebo-controlled study that included 1177 patients with completely resected stage IB (T2a ≥4 cm), II, or IIIA NSCLC who had not received neoadjuvant radiotherapy or chemotherapy. Study participants were randomly assigned to receive pembrolizumab 200mg (n=506) or placebo (n=504) intravenously every 3 weeks; 86% (n=1010) received adjuvant platinum-based chemotherapy following resection.
In the overall study population, findings showed a statistically significant improvement in disease-free survival (DFS; primary endpoint) for patients treated with pembrolizumab compared with placebo (hazard ratio, 0.73; 95% CI, 0.60-0.89). Median DFS was reported to be 58.7 months (95% CI, 39.2-not reached) in the pembrolizumab arm and 34.9 months (95% CI, 28.6-not reached) in the placebo arm. Among patients who did not receive adjuvant chemotherapy (n=167), the DFS HR was 1.25 (95% CI, 0.76-2.05). Overall survival results were not mature at the time of analysis.
With the exception of hypothyroidism (22%), hyperthyroidism (11%), and pneumonitis (7%), adverse reactions observed in the KEYNOTE-091 study were similar to those seen in NSCLC patients treated with Keytruda as a single agent; fatal myocarditis was reported in 2 patients.
Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody. This approval marks the fifth indication for Keytruda in the treatment of NSCLC.
- FDA approves Keytruda® (pembrolizumab) as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 centimeters), II, or IIIA non-small cell lung cancer (NSCLC). News release. January 27, 2023. https://www.businesswire.com/news/home/20230127005078/en/FDA-Approves-KEYTRUDA%C2%AE-pembrolizumab-as-Adjuvant-Treatment-Following-Surgical-Resection-and-Platinum-Based-Chemotherapy-for-Patients-With-Stage-IB-T2a-%E2%89%A54-Centimeters-II-or-IIIA-Non-Small-Cell-Lung-Cancer-NSCLC
- Keytruda. Package insert. Merck; 2023. Accessed January 27, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s128lbl.pdf
This article originally appeared on MPR
Log in to continue reading this article.
Don’t miss out on today’s top content on The Medical Bag. Register for free and gain unlimited access to the latest in medical news, and lifestyle and business advice, with personalized daily picks for you. There’s something for every health care professional on The Medical Bag.
Want to read more?
Please login or register first to view this content.